表皮生长因子受体信号通路在非小细胞肺癌中的作用：从分子机制到治疗机会。
EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
机构信息
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
出版信息
Cells. 2022 Apr 14;11(8):1344. doi: 10.3390/cells11081344.
Abstract
Lung cancer is the leading cause of cancer death worldwide [...].
摘要
肺癌是全球癌症死亡的主要原因[... ]。
相似文献
1
EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities.表皮生长因子受体信号通路在非小细胞肺癌中的作用：从分子机制到治疗机会。
Cells. 2022 Apr 14;11(8):1344. doi: 10.3390/cells11081344.
2
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.双重 PI3K/mTOR 抑制剂 BEZ235 可限制肺癌肿瘤的生长，而与 EGFR 状态无关，是联合治疗方案中的有力辅助药物。
J Exp Clin Cancer Res. 2019 Jul 1;38(1):282. doi: 10.1186/s13046-019-1282-0.
3
Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer.Dynasore 诱导的表皮生长因子受体外显子 19 缺失突变体的强烈泛素化抑制非小细胞肺癌的细胞生长和迁移。
Int J Biochem Cell Biol. 2018 Dec;105:1-12. doi: 10.1016/j.biocel.2018.09.017. Epub 2018 Sep 28.
4
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.端锚聚合酶和经典 Wnt 通路保护肺癌细胞免受 EGFR 抑制。
Cancer Res. 2012 Aug 15;72(16):4154-64. doi: 10.1158/0008-5472.CAN-11-2848. Epub 2012 Jun 27.
5
MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma.丝裂原活化蛋白激酶（MAPK）信号通路：治疗非小细胞肺癌的潜在靶点。
Future Med Chem. 2019 Apr;11(8):793-795. doi: 10.4155/fmc-2018-0468. Epub 2019 Apr 17.
6
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.肺癌中脂质代谢的重编程：以 EGFR 突变型非小细胞肺癌为重点的概述。
Cells. 2022 Jan 25;11(3):413. doi: 10.3390/cells11030413.
7
[Advances of heterogeneity of EGFR in non-small cell lung cancer].[非小细胞肺癌中表皮生长因子受体异质性的研究进展]
Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):890-3. doi: 10.3779/j.issn.1009-3419.2011.11.11.
8
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌耐药性：生物学基础与治疗策略。
Clin Transl Oncol. 2014 Apr;16(4):339-50. doi: 10.1007/s12094-013-1143-9. Epub 2013 Dec 4.
9
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.PLAUR通过EGFR/P-AKT/生存素信号通路赋予对吉非替尼的抗性。
Cell Physiol Biochem. 2018;47(5):1909-1924. doi: 10.1159/000491071. Epub 2018 Jun 29.
10
MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type Family Members.MERTK 促进表达野生型家族成员的非小细胞肺癌对不可逆 EGFR 酪氨酸激酶抑制剂的耐药性。
Clin Cancer Res. 2018 Dec 15;24(24):6523-6535. doi: 10.1158/1078-0432.CCR-18-0040. Epub 2018 Sep 7.
引用本文的文献
1
NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway.NRP1过表达可能通过激活PI3K/AKT信号通路增强非小细胞肺癌对奥希替尼的耐药性。
Am J Cancer Res. 2024 Dec 15;14(12):5680-5696. doi: 10.62347/RLVZ6860. eCollection 2024.
本文引用的文献
1
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.肺癌中脂质代谢的重编程：以 EGFR 突变型非小细胞肺癌为重点的概述。
Cells. 2022 Jan 25;11(3):413. doi: 10.3390/cells11030413.
2
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.突变型 EGFR 驱动的非小细胞肺癌的新兴分子依赖性。
Cells. 2021 Dec 16;10(12):3553. doi: 10.3390/cells10123553.
3
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned.早期肺癌中预测 EGFR 靶向治疗：不放过任何蛛丝马迹。
Cells. 2021 Oct 7;10(10):2685. doi: 10.3390/cells10102685.
4
Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.液体活检在非小细胞肺癌疾病监测中的应用：生物学与临床的联系。
Cells. 2021 Jul 28;10(8):1912. doi: 10.3390/cells10081912.
5
Dynamic Evaluation of Circulating miRNA Profile in -Mutated NSCLC Patients Treated with EGFR-TKIs.动态评估 EGFR-TKIs 治疗 - 突变型 NSCLC 患者的循环 miRNA 谱。
Cells. 2021 Jun 16;10(6):1520. doi: 10.3390/cells10061520.
6
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with Mutations.肺癌中具有突变的表皮生长因子受体酪氨酸激酶抑制剂耐药性。
Cells. 2021 Jun 24;10(7):1590. doi: 10.3390/cells10071590.
7
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.表皮生长因子受体表达与非小细胞肺癌靶向治疗耐药模式：综述。
Cells. 2021 May 14;10(5):1206. doi: 10.3390/cells10051206.
8
OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.OPALS：使用五种重新定位药物的奥希替尼辅助治疗肺腺癌或胶质母细胞瘤的新方法。
Cells. 2021 May 10;10(5):1148. doi: 10.3390/cells10051148.
Zotero 插件